Alopecia Universalis Treated With Tofacitinib: The Role of JAK/STAT Inhibitors in Hair Regrowth

Lauren Schwartzberg; Amy Spizuoco

doi:10.12788/cutis.0874

Alopecia Universalis Treated With Tofacitinib: The Role of JAK/STAT Inhibitors in Hair Regrowth

Cutis. 2023 Nov;112(5):E5-E9. doi: 10.12788/cutis.0874.

Authors

Lauren Schwartzberg¹, Amy Spizuoco¹

Affiliation

¹ Dr. Schwartzberg is from the Department of Medicine, Lehigh Valley Health Network, Allentown, Pennsylvania. Dr. Spizuoco is from True Dermatology PLLC, New York, New York, and the Department of Dermatology, Mount Sinai Beth Israel Hospital, New York.

PMID: 38091428
DOI: 10.12788/cutis.0874

Abstract

Alopecia universalis is alopecia areata (AA) with total-body involvement of hair loss. The disease progression is due to autoimmune T cells. We present a case of a patient with alopecia universalis who was successfully treated with tofacitinib.

Publication types

Case Reports

MeSH terms

Alopecia / drug therapy
Alopecia Areata* / drug therapy
Hair
Humans
Janus Kinase Inhibitors* / therapeutic use
Pyrroles / therapeutic use

Substances

Janus Kinase Inhibitors
tofacitinib
Pyrroles

Supplementary concepts

Alopecia universalis